Anti-VEGF
Showing 1 - 25 of >10,000
Macular Edema Due to Type 2 Diabetes Trial in Hangzhou (Anti-VEGF, subthreshold micropulse laser)
Recruiting
- Macular Edema Due to Type 2 Diabetes Mellitus
- Anti-VEGF
- subthreshold micropulse laser
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Feb 26, 2023
Following Intensive Anti-VEGF Therapy in Wet AMD
Completed
- Age-Related Macular Degeneration
- Anti-VEGF
-
Budapest, Hungary
- +1 more
Dec 28, 2022
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept Trial in Tianjin (Vitrectomy combined with ILM peeling, Conbercept
Not yet recruiting
- Diabetic Macular Edema
- +2 more
- Vitrectomy combined with ILM peeling
- Conbercept intravitreal injection
-
Tianjin, Tianjin, ChinaTianjin medical university eye hosipital
Feb 14, 2023
Recurrent Brain Tumor Trial in Houston (biological, other, radiation)
Active, not recruiting
- Recurrent Brain Neoplasm
- Bevacizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment Trial in Monastir (Bevacizumab Injection
Recruiting
- Proliferative Diabetic Retinopathy
- +2 more
- Bevacizumab Injection [Avastin]
- Peripheral Retinal Cryoapplication
-
Monastir, TunisiaFattouma Bourguiba University Hospital - Ophthalmology Departmen
Aug 22, 2022
Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)
Completed
- Advanced Cancer
- Dasatinib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 21, 2022
Proliferative Diabetic Retinopathy Trial in Beijing (proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use)
Recruiting
- Proliferative Diabetic Retinopathy
- proactive Anti-VEGF (conbercept) use
- passive Anti-VEGF (conbercept) use
-
Beijing, Beijing, ChinaPeking University Third Hospital
Dec 13, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Neovascular Age-related Macular Degeneration Trial in United States (CLS-AX, Anti-VEGF)
Completed
- Neovascular Age-related Macular Degeneration
- CLS-AX
- Anti-VEGF
-
Phoenix, Arizona
- +10 more
Dec 1, 2022
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in
Not yet recruiting
- Ovarian Clear Cell Adenocarcinoma
- +14 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +4 more
-
Buffalo, New York
- +1 more
Dec 16, 2022
s in Wet AMD in Active Smokers
Completed
- Wet Age-related Macular Degeneration
- Medical Data extraction
-
Brussels, BelgiumCHU Brugmann
Mar 7, 2022
Adult Diabetic Macular Edema and Suboptimal Response to
Not yet recruiting
- Diabetic Macular Edema
- (no location specified)
Jul 31, 2023
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- HAIC
- +8 more
-
Quanzhou, Fujian, China
- +1 more
Jan 26, 2023
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo
Not yet recruiting
- Fallopian Tube Carcinosarcoma
- +10 more
- Bevacizumab
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 29, 2022
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial
Recruiting
- Resectable Hepatocellular Carcinoma
- +4 more
- Atezolizumab
- +2 more
-
Houston, Texas
- +1 more
Oct 12, 2022
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- TACE
- +8 more
-
Quanzhou, Fujian, China
- +3 more
Jan 29, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 17, 2022
Exudative Age Related Macular Degeneration Trial in Winston-Salem (Ranibizumab, Photodynamic laser treatment (PDT),
Not yet recruiting
- Exudative Age Related Macular Degeneration
- Ranibizumab
- +3 more
-
Winston-Salem, North CarolinaWake Forest Health Sciences
Nov 28, 2022
Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,
Not yet recruiting
- Metastatic Colorectal Carcinoma
- +3 more
- Bevacizumab
- +11 more
- (no location specified)
May 9, 2023
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Retinal Telangiectasis, Coats Disease Trial in France (Anti-VEGF injections of bevacizumab, Laser)
Recruiting
- Retinal Telangiectasis
- Coats Disease
- Anti-VEGF injections of bevacizumab
- Laser
-
Cergy-Pontoise, France
- +4 more
Dec 17, 2021
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma Trial in Los Angeles, San Diego (biological, drug, other, genetic)
Active, not recruiting
- Giant Cell Glioblastoma
- +2 more
- bevacizumab
- +5 more
-
Los Angeles, California
- +2 more
Feb 10, 2022